Application of Ly6G antibody in treatment of pneumonia caused by novel coronavirus
By applying Ly6G antibody to target neutrophils, deplete neutrophils, and inhibit NET formation, the treatment challenge of severe pneumonia caused by the novel coronavirus was solved, and effective relief and symptom improvement were achieved for multiple infections.
Patent Information
- Application Number
- CN202511681904.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-17
- Publication Date
- 2026-01-30
AI Technical Summary
There is a lack of effective drugs for treating severe and critical pneumonia caused by the novel coronavirus, especially for severe pneumonia caused by repeated infections of the novel coronavirus, where existing treatments are limited and lack specificity.
By applying Ly6G antibody or its antigen-binding fragment, neutrophils are targeted and depleted, NET formation is inhibited, cytokine and chemokine expression levels are reduced, lung inflammatory infiltration is alleviated, and symptoms caused by novel coronavirus infection are relieved.
It effectively reduces pulmonary inflammatory infiltration, decreases the expression of cytokines and NETs-related proteins, and inhibits NETs formation, providing a treatment strategy for severe pneumonia caused by novel coronavirus infection, especially multiple infections, and significantly improves the condition.
Smart Images

Figure CN121422207A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine, specifically relating to the application of Ly6G antibody in the treatment of pneumonia caused by the novel coronavirus. Background Technology
[0002] The novel coronavirus has swept the globe, causing numerous waves of infection. Despite progress in testing, diagnosis, and treatment, the limited effectiveness of vaccines and antiviral drugs means that pneumonia caused by the novel coronavirus remains a significant public health problem worldwide. Since its emergence, the novel coronavirus has spawned multiple mutant strains, among which the Omicron variant, due to its rapid antigenic mutations, frequently triggers breakthrough infections and reinfections. The emergence of these variants may alter the clinical symptoms of viral infection, and the continuous emergence of mutants presents new challenges to research on the transmission, prevention, and treatment of the novel coronavirus.
[0003] Currently, most patients infected with the novel coronavirus have relatively mild clinical symptoms, often manifesting as fever, cough, or sore throat, with most experiencing spontaneous symptom relief within a week. However, a portion of patients infected with the novel coronavirus (including those reinfected) will progress to severe or critical illness as their condition worsens. Severe pneumonia caused by the novel coronavirus, due to extensive alveolar damage and lung structure destruction, leads to restrictive ventilation dysfunction, impaired gas exchange, and severe respiratory failure, resulting in a persistently high mortality rate. Currently, however, there are no effective drugs to treat severe and critical pneumonia caused by the novel coronavirus. Summary of the Invention
[0004] In view of this, in order to overcome the shortcomings of the prior art, the present invention is proposed.
[0005] The first aspect of this invention provides for any of the following applications:
[0006] (1) The use of Ly6G antibody or Ly6G antigen-binding fragment in the preparation of drugs for the treatment and / or prevention of novel coronavirus infection;
[0007] (2) The use of Ly6G antibody or Ly6G antigen binding fragment in the preparation of drugs for the treatment and / or prevention of diseases or symptoms caused by novel coronavirus infection.
[0008] In this invention, the term "treatment and / or prevention" can refer to therapeutic treatments or preventative measures where the objective is to prevent or slow (mitigate) an undesirable physical condition, impairment, or disease, or to achieve a beneficial or desired clinical outcome. Beneficial or desired clinical outcomes include, but are not limited to, symptom relief; reduction of the severity of a condition, impairment, or disease; stabilization (i.e., non-exacerbation) of the state of a condition, impairment, or disease; delaying the onset of a condition, impairment, or disease or slowing its progression; improving the state of a condition, impairment, or disease; and relief (whether partial or complete) (whether detectable or undetectable) or improvement of a condition, impairment, or disease. Treatment may include causing a clinically noticeable response without excessive side effects. Treatment also includes extended survival compared to expected survival without treatment.
[0009] Furthermore, the antibodies include monoclonal antibodies, polyclonal antibodies, and recombinant antibodies.
[0010] Furthermore, the antigen-binding fragments include Fab, Fab′, F(ab′)2, single-chain antibody scFv, and nanobody VHH.
[0011] Furthermore, the Ly6G antibody is an antibody manufactured by Bio Cell with the product number BE0075-1.
[0012] Furthermore, the novel coronavirus infection includes first-time infection with the novel coronavirus.
[0013] Furthermore, the novel coronavirus infection includes multiple infections following an initial infection with the novel coronavirus.
[0014] Furthermore, the novel coronavirus infection in the first instance and the novel coronavirus infection in multiple instances belong to different lineages of the same variant strain or are different variant strains.
[0015] Furthermore, the novel coronavirus infection in the first instance and the novel coronavirus infection in multiple instances belong to different lineages of the same variant strain.
[0016] Furthermore, the mutant strains include Alpha mutants, Beta mutants, Gamma mutants, Delta mutants, Omicron mutants, and other mutant strains.
[0017] Furthermore, the mutant strain is selected from the Omicron mutant strain.
[0018] Furthermore, the Omicron variants include BA.1, BA.2, BA.3, BA.4, BA.5 or their progeny lineages.
[0019] Furthermore, the BA.2 progeny lineage includes XBB.
[0020] Furthermore, the Omicron mutant strain is selected from BA.5 and XBB.
[0021] Furthermore, the novel coronavirus of the first infection was selected from BA.5.
[0022] Furthermore, the novel coronaviruses that caused the multiple infections were selected from XBB.
[0023] Furthermore, the disease or condition caused by the novel coronavirus infection is selected from one or more of the following: respiratory infection, acute respiratory syndrome, pneumonia, gastroenteritis, cough, fever, chills, vomiting, headache, chills, shortness of breath, cytokine storm.
[0024] Furthermore, the disease or symptom caused by the novel coronavirus infection is selected from pneumonia.
[0025] Furthermore, the pneumonia in question is severe pneumonia caused by the novel coronavirus.
[0026] Furthermore, the severe pneumonia caused by the novel coronavirus, compared with the mild pneumonia caused by the novel coronavirus, exhibits one or more of the following symptoms: increased pulmonary inflammatory infiltration, increased cytokines, increased chemokines, increased NETs formation, and elevated NETs-related protein expression levels.
[0027] Furthermore, the NETs-related proteins include citH3, NE, MPO-DNA, and PAD4.
[0028] A second aspect of the present invention provides a pharmaceutical composition for treating and / or preventing novel coronavirus infection or diseases or symptoms caused by such infection, said pharmaceutical composition being selected from the Ly6G antibody or Ly6G antigen-binding fragment described in the first aspect of the present invention.
[0029] Furthermore, the pharmaceutical composition also includes a pharmaceutically acceptable carrier and / or excipients.
[0030] The third aspect of the present invention provides any of the following applications:
[0031] (1) Application of Ly6G antibody or Ly6G antigen-binding fragment in the preparation of drugs to reduce the degree of inflammatory infiltration in the lungs;
[0032] (2) Application of Ly6G antibody or Ly6G antigen-binding fragment in the preparation of drugs that reduce the expression levels of cytokines or chemokines;
[0033] Furthermore, the cytokines include IL-6, IFN-α, IFN-γ, and TNF-α;
[0034] Furthermore, the chemokines include CCL2, CCL4, CXCL10, and GM-CSF;
[0035] (3) Application of Ly6G antibody or Ly6G antigen-binding fragment in the preparation of drugs that inhibit NET formation;
[0036] (4) Application of Ly6G antibody or Ly6G antigen-binding fragment in the preparation of drugs that reduce the expression level of NETs-related proteins.
[0037] Furthermore, the NETs-related proteins include citH3, NE, MPO-DNA, and PAD4.
[0038] The fourth aspect of the present invention provides any of the following methods:
[0039] (1) A method for reducing the expression level of cytokines or chemokines in vitro, the method comprising administering a Ly6G antibody or a Ly6G antigen-binding fragment;
[0040] (2) A method for inhibiting NETs formation in vitro, the method comprising administering a Ly6G antibody or a Ly6G antigen-binding fragment;
[0041] (3) A method for reducing the expression level of NETs-related proteins in vitro, the method comprising administering a Ly6G antibody or a Ly6G antigen-binding fragment.
[0042] The advantages and beneficial effects of this invention are as follows:
[0043] This invention provides the application of Ly6G antibody in the treatment of pneumonia caused by the novel coronavirus. The Ly6G antibody can effectively reduce the degree of pulmonary inflammatory infiltration, decrease the expression levels of cytokines, chemokines, or NETs-related proteins, and inhibit NET formation after novel coronavirus infection. This invention provides a novel treatment strategy for novel coronavirus infection, especially severe pneumonia caused by repeated novel coronavirus infections. Attached Figure Description
[0044] Figure 1 This is a graph showing the degree of inflammatory infiltration in the lungs of mice;
[0045] Figure 2 This is a graph showing the expression levels of cytokines IL-6, IFN-α, IFN-γ, TNF-α, and chemokines CCL2, CCL4, CXCL10, and GM-CSF.
[0046] Figure 3 This is a diagram showing the results of NETs forming;
[0047] Figure 4 This is a graph showing the expression levels of NETs-related proteins. Detailed Implementation
[0048] The present invention will be further described below with reference to embodiments. The following description is merely a preferred embodiment of the present invention and is not intended to limit the invention in any other way. Any person skilled in the art may make equivalent modifications to the disclosed technical content to create equivalent embodiments. Any simple modifications or equivalent changes made to the following embodiments based on the technical essence of the present invention without departing from the scope of the invention are all within the protection scope of the present invention.
[0049] Antibody
[0050] In this invention, the Ly6G antibody or Ly6G antigen-binding fragment specifically recognizes and binds to Ly6G, which is a glycosylated phosphatidylinositol-anchored cell surface protein.
[0051] In this invention, the antibody includes monoclonal antibody, polyclonal antibody, and recombinant antibody.
[0052] As used herein, a "monoclonal antibody" refers to an antibody molecule or antibody formulation that shares a common heavy chain amino acid sequence and a common light chain amino acid sequence, as opposed to a "polyclonal" antibody formulation containing a mixture of antibodies with different amino acid sequences. Monoclonal antibodies can be produced using several known techniques such as phage, bacterial, yeast, or ribosome display, as well as the classic method exemplified by antibodies derived from hybridomas. Therefore, the term "monoclonal" is used to refer to all antibodies derived from a single nucleic acid clone.
[0053] As used in this article, the term "polyclonal antibody" refers to a mixture of antibodies produced by multiple B cell clones after immunization in mammals (such as humans, rabbits, sheep, mice, and horses). Because the antigen contains multiple determinants, it stimulates different B cells to produce antibodies against multiple epitopes.
[0054] As used herein, the term "recombinant antibody" refers to an antibody manufactured, expressed, produced, or isolated by recombinant methods, such as antibodies expressed using a recombinant expression vector transfected into host cells; antibodies isolated from a recombinant antibody library; or antibodies manufactured, expressed, produced, or isolated by any other means, such as antibodies manufactured, expressed, produced, or isolated by assembling a specific immunoglobulin gene sequence (such as the human immunoglobulin gene sequence) with other DNA sequences.
[0055] In this invention, the antibodies include chimeric antibodies, modified antibodies, SDR transplantation antibodies, antigen epitope-directed selection antibodies, surface remodeling antibodies, framework region replacement antibodies, and fully humanized antibodies.
[0056] As used herein, a “chimeric antibody” refers to an antibody whose variable domain sequence, derived from a non-human mammal species (e.g., mouse), is grafted onto a constant domain sequence derived from a human antibody.
[0057] As used herein, the “modified antibody” refers to the transplantation of the complementarity-determining region (CDR) of an antibody variable region derived from a non-human mammalian species (e.g., mouse) into the backbone region (FR) of a human antibody variable region.
[0058] The "CDR," also known as the "complementarity-determining region," "CDR region," or "hypervariant region," is a region in the antibody's variable region that is highly variable in sequence and forms a structurally defined loop ("hypervariant loop") and / or contains antigen contact residues ("antigen contact sites"). The CDR is primarily responsible for binding to antigen epitopes.
[0059] "Modified antibodies" include antibodies with complete CDR transplantation and antibodies with partial CDR transplantation.
[0060] Complete CDR transplantation antibody: Six CDRs from a non-human antibody are cloned into the corresponding FRs of a human antibody using methods such as PCR to construct a new antibody. Compared with chimeric antibodies, CDR transplantation further reduces the content of heterologous sequences in the antibody and reduces antibody heterology.
[0061] Partial CDR transplantation antibodies: The properties of six CDRs on non-human antibodies are studied to identify the CDRs necessary for binding antigens in the antibody. These CDRs are then transplanted onto human antibody FR, resulting in lower immunogenicity than fully CDR transplanted antibodies.
[0062] SDR transfer antibodies: Based on partial CDR transplantation, a few residues from specific regions (SDRs) of the CDR that are specifically recognized and bound to the antigen are transplanted to the corresponding positions on the human antibody. These mainly include: SDR residues exposed to the outside of the CDR that are closely related to antigen binding; residues related to maintaining the 4th-order structure of the antibody's V region; amino acid position 71 of the light and heavy chains; and residues at the N-terminus of the antibody.
[0063] Antigen epitope-directed antibody selection: Antigen epitope-directed selection is a humanization strategy developed based on phage antibody library technology. Taking non-human antibodies derived from mice as an example, antigen epitope-directed selection uses the variable regions of light and heavy chain genes as basic units to construct human heavy chain mouse light chain and human light chain mouse heavy chain hybrid antibody libraries. Using a phage surface selection system, human heavy chain mouse light chain genes and human light chain mouse heavy chain genes are screened separately. Then, the human light and heavy chain genes are mixed and screened to obtain fully humanized antibody light and heavy chain genes that recognize the same epitopes as the parent mouse monoclonal antibody.
[0064] Surface-remodeled antibodies: Surface remodeling is a humanization technique directly based on the three-dimensional structure of antibodies. Taking non-human antibodies derived from mice as an example, the immunogenicity of the V region of mouse monoclonal antibodies largely stems from the motility and solution accessibility of surface residues in this region (solution surface accessible residues (SAR): amino acid residues that can come into contact with the solvent when the antibody dissolves). Amino acids with high solution accessibility may have strong antigenicity. Surface remodeling emphasizes replacing highly surface accessible amino acid residues in the variable regions of the light and heavy chains of mouse-derived antibodies with corresponding human amino acid residues based on the precise or modeled structure of antigen-antibody interactions, while retaining the mouse-derived CDR region and embedded amino acid residues. Surface remodeling can maximize the preservation of antibody binding activity while improving its humanization degree, making it a relatively ideal humanization method.
[0065] Frame region replacement antibodies: Unlike CDR transplantation antibodies, the frame region replacement method does not search for human antibody frame regions similar to those in murine antibodies. Instead, it establishes a human antibody frame region library based on human germline genes, and then transplants the six CDRs (three light chains and three heavy chains) of the heterologous antibody into the frame regions of the human germline genes. The corresponding antibody combination library can then be screened using antigens. This method can not only be used for humanized antibodies but is also a more general antibody modification method. Through screening, it may even be possible to find human antibodies with stronger affinity than parental murine antibodies.
[0066] In this invention, the antibodies include monospecific antibodies and multispecific antibodies.
[0067] In this invention, the multispecific antibody is a type of antibody that can simultaneously bind to two or more different antigenic epitopes or antigens.
[0068] In some implementations, the multispecific antibody is bispecific, trispecific, quadrispecific, or even more specific.
[0069] In some implementations, the multispecific antibody is bispecific.
[0070] In some embodiments, the multispecific antibody is an antibody that simultaneously binds to different antigenic epitopes of Ly6G.
[0071] In this invention, the antigen-binding fragments include Fab, Fab′, F(ab′)2, single-chain antibody scFv, and nanobody VHH.
[0072] Fab: Fab is a functional unit of a monoclonal antibody molecule, which contains the heavy chain variable region VH, the heavy chain constant region CH1, the light chain variable region VL, and the light chain constant region CL. It does not contain the Fc fragment and has a molecular weight of approximately 50 kDa.
[0073] scFv: scFv is the variable region of the monoclonal antibody molecule, namely VH+VL, with a molecular weight of approximately 25 kDa.
[0074] VHH: Unlike Fab and scFv, VHH originates from heavy chain antibodies (a type of antibody that naturally lacks a light chain). VHH is the variable region of the heavy chain in a heavy chain antibody, with a molecular weight of approximately 15 kDa. The molecular weight of VHH is only one-tenth that of conventional antibodies, and its size is in the nanometer range, hence it is also called a nanobody (Nano-antibody). Because it has a single structural domain, it is also called a single-domain antibody (SdAbs).
[0075] Novel coronavirus infection
[0076] In some implementations, the novel coronavirus infection includes a first infection with the novel coronavirus.
[0077] In some implementations, the novel coronavirus infection includes multiple infections following an initial infection with the novel coronavirus.
[0078] In some implementations, the number of times is not limited and can be two, three, four, or more.
[0079] In some implementations, the number of times is selected from two.
[0080] In some implementations, the disease or condition caused by the novel coronavirus infection includes the disease or condition caused by multiple infections with the novel coronavirus after the initial infection.
[0081] Pharmaceutical Composition
[0082] The pharmaceutically acceptable carriers and / or excipients described in this invention include any substance suitable for humans and / or mammals without excessive adverse side effects (e.g., toxicity, irritation, and allergic reactions), i.e., having a reasonable benefit / risk ratio. The pharmaceutically acceptable carriers and / or excipients are used as needed to aid in the stability of the formulation or to help improve its activity or bioavailability, or to produce an acceptable taste or odor when taken orally. The pharmaceutical composition thus formulated can be administered as needed using any appropriate method of administration known to those skilled in the art, and when using the pharmaceutical composition, a safe and appropriate dosage of the pharmaceutical composition described in this invention is administered to the subject.
[0083] In some embodiments, the pharmaceutically acceptable carrier and / or excipients include physiological saline, D5W, Ringer's lactate, hyaluronidase, solution tension regulators, solution osmotic pressure regulators, lyophilization protectants for lyophilized powders, viscosity-reducing excipients, buffer solutions, or surfactants.
[0084] In some embodiments, the solution tension regulator includes sodium chloride or arginine.
[0085] In some embodiments, the solution osmotic pressure regulator includes sucrose, trehalose, sorbitol, or mannitol.
[0086] In some embodiments, the freeze-drying protectant of the freeze-dried powder includes trehalose or sucrose.
[0087] In some embodiments, the viscosity-reducing excipients include arginine, sodium chloride, glycine, proline, or lysine.
[0088] In some embodiments, the buffer solution includes histidine, phosphoric acid, citric acid, acetate, succinic acid, lactic acid, tromethorphan, aspartic acid, glutamic acid, adipic acid, or MES.
[0089] In some embodiments, the surfactant includes polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350.
[0090] In some embodiments, the pharmaceutical composition can be administered in any convenient pharmaceutical dosage form.
[0091] In some implementations, the dosage form includes gastrointestinal dosage forms and non-gastrointestinal dosage forms.
[0092] In some implementations, the dosage form is selected from non-gastrointestinal dosage forms.
[0093] In some implementations, the non-gastrointestinal dosage forms include, but are not limited to, injectable dosage forms, respiratory dosage forms, cavity dosage forms, mucosal dosage forms, and skin dosage forms.
[0094] In some embodiments, the injectable dosage forms include, but are not limited to, various injectables such as intravenous injections, intramuscular injections, subcutaneous injections, intradermal injections, and intracavitary injections; the respiratory dosage forms include, but are not limited to, sprays, aerosols, and powder inhalers; the cavity dosage forms include, but are not limited to, suppositories, aerosols, effervescent tablets, drops, and pills, for use in the rectum, vagina, urethra, nasal cavity, and ear canal; the mucosal dosage forms include, but are not limited to, eye drops, nasal drops, ointments, mouthwashes, sublingual tablets, adhesive tablets, and patches; and the skin dosage forms include, but are not limited to, topical solutions, lotions, liniments, ointments, plasters, pastes, and patches.
[0095] In this invention, the pharmaceutical composition is administered to the patient at a pharmaceutically effective dose. A "pharmaceutically effective dose" means a dose sufficient to produce the desired effect for the condition to which it is administered. The precise dose may require different doses depending on the activity of the compound, the method of administration, the nature and severity of the condition, the patient's age and weight. Dosing can be implemented through a single administration in the form of an individual dose unit (or, otherwise, several smaller dose units) and also through multiple administrations of subdivided doses at specific time intervals.
[0096] In some embodiments, the pharmaceutical composition can be administered before or after infection.
[0097] When there is more than one infection, the drug composition can be administered before the first infection, after the first infection, before multiple infections, after multiple infections, or before the first infection, after the first infection, before multiple infections, or after multiple infections.
[0098] When there are more than two infections, the drug composition can also be administered between multiple infections.
[0099] In some embodiments, the pharmaceutical composition is administered immediately after the first infection with the novel coronavirus.
[0100] In some embodiments, the pharmaceutical composition is administered 1 to 28 days after the first infection with the novel coronavirus.
[0101] In some embodiments, the pharmaceutical composition is administered 28 days after the first infection.
[0102] In some embodiments, the pharmaceutical composition is administered in a pharmaceutically effective amount.
[0103] Example 1
[0104] 1. Experimental Materials
[0105] 1.1 Experimental Virus
[0106] BA.5 strain: SARS-CoV-2 / human / CHN / GD-5 / 2022 (Gene Bank: OP678016) OmicronXBB.1 (Genbank ID: PQ312715).
[0107] 1.2 Experimental Animals and Cells
[0108] Female BALB / c mice aged 6-8 weeks were purchased from Beijing Huafukang Biotechnology Co., Ltd.
[0109] 1.3 Experimental Apparatus
[0110] Immunofluorescence microscope (Leica, USA), cell counter (DeNOVIX, USA), centrifuge (Eppendorf, Germany).
[0111] 1.4 Experimental Reagents and Consumables
[0112] Anti-mouse Ly6G antibody (Bio Cell, BE0075-1), antibody diluent (Abixin, abs9299), four-color multiplex immunohistochemical staining kit (Abixin, abs50028), cith3 ELISA kit (citrullinated histone 3, Shanghai Keabo Biotechnology Co., Ltd., CB11403-Mu), NE (neutrophil elastase, Shanghai Keabo Biotechnology Co., Ltd., CB10847-Mu), PAD4 ELISA kit (peptidyl arginine deiminase 4, Shanghai Keabo Biotechnology Co., Ltd., CB11404-Mu), MPO-DNA ELISA kit (myeloperoxidase-DNA complex, Shanghai Keabo Biotechnology Co., Ltd., CB14718-Mu), LEGENDplex™ Proinflammatory Chemokine Panel (13-plex) (Mouse) (Biolegend, 740446), EPX360-26092-901 MO CYTO / CHEMO PANEL 1A Reagent Kit (ThermoFisher Scientific, EPX360-26092-901)
[0113] 2. Experimental Methods
[0114] Animal experiments:
[0115] In the presence of primary infection with the Omicron BA.5 strain, reinfection with the XBB variant induced a more severe inflammatory response, leading to exacerbated pathological damage to lung tissue. Pathologically, this manifested as significant weight loss, increased neutrophil infiltration in lung tissue, a phenotype characterized by aggravated inflammatory infiltration accompanied by abnormal citH3 / MPO-DNA deposition, excessive NETs release, and worsening lung injury. Therefore, a mouse model initially infected with BA.5 followed by the XBB strain was selected as a model for investigating the therapeutic effects of drugs in patients with severe pneumonia caused by the novel coronavirus.
[0116] Female BALB / c mice aged 6-8 weeks (n=5 per group) were anesthetized and injected intranasally with 50 μL (10 5 TCID 50BA.5 virus. Each mouse was monitored daily for signs of disease and weight changes until 27 dpi. 250 μg / mouse of Anti-mouse Ly6G antibody was injected via tail vein. 24 h later, the mice were reinfected with the XBB strain. Three dpi after reinfection, each group of mice was euthanized by cervical dislocation, and fresh lung tissue was collected for subsequent analysis of neutrophil trap (NETs) related indicators, such as citH3 and MPO-DNA complex.
[0117] All experimental procedures related to novel coronavirus (SARS-CoV-2 virus) infection in this study were conducted within an ABSL-3 laboratory. Animal experiments were approved under animal ethics review, with approval number BLL23007.
[0118] Immunofluorescence staining
[0119] 1) The sections were soaked in xylene I / II for 10 minutes each; then hydrated with a gradient of ethanol (100%-95%-80%-70%) for 5 minutes each, and rinsed with PBS for 5 minutes each time, 3 times.
[0120] 2) Immerse the sections in sodium citrate buffer (pH 6.0), heat at 95°C for 20 minutes for repair, and then allow to cool naturally to room temperature;
[0121] 3) Infiltrate with 0.5% Triton X-100 (prepared with PBS) for 10 minutes, wash with PBS for 5 minutes × 3 times, and block with 5% goat serum (prepared with PBS) at room temperature for 60 minutes.
[0122] 4) Add diluted primary antibodies: MPO (abcam, ab134132, 1:1000), citH3 (abcam, ab281584, 1:2000), PAD4 (abcam, ab96758, 1:1000), and incubate overnight at 4°C in a humidified chamber.
[0123] 5) The next day, warm to room temperature for 45 minutes, wash with PBS for 5 minutes × 5 times, add the corresponding species fluorescent secondary antibody (such as Alexa Fluor 488 / 594 labeled), incubate at 37°C in the dark for 60 minutes, and wash with PBS for 5 minutes × 5 times.
[0124] 6) Add DAPI (1 μg / mL) to stain the nuclei for 10 minutes, then rinse with PBS;
[0125] 7) Mount the slides with anti-fluorescence quenching mounting medium and dry at room temperature in the dark;
[0126] 8) Images were acquired using a fluorescence microscope (Leica DMi8) with 20× / 40× objectives.
[0127] Enzyme-linked immunosorbent assay
[0128] 1) The bronchoalveolar lavage fluid sample was centrifuged at 4°C and 12,000×g for 15 minutes, and the supernatant was collected for later use;
[0129] 2) Add 100 μL of standard / sample supernatant to each well of a pre-coated 96-well plate according to the kit instructions, incubate at 37°C for 60 minutes, discard the solution, and wash 5 times with washing buffer (PBS containing 0.05% Tween-20);
[0130] 3) Add 100 μL of biotinylated detection antibody to each well, incubate at 37°C for 60 minutes, and wash 5 times;
[0131] 4) Add 100 μL of horseradish peroxidase (HRP)-labeled streptavidin, incubate at 37°C in the dark for 30 minutes, and wash 5 times;
[0132] 5) Add 100 μL of TMB substrate solution, incubate at room temperature in the dark for 15 minutes, and then add 50 μL of 2M H2SO4 stop solution to terminate the reaction.
[0133] 6) Use an ELISA reader to measure the absorbance (OD value) at 450 nm.
[0134] Cytokine detection
[0135] Collect bronchoalveolar lavage fluid samples from mice, centrifuge at 10,000 rpm at 4℃ for 20 min, and take 30 μL of supernatant for sample preparation.
[0136] Take 35 μL of the prepared sample (diluted serum or lung sample) and add LEGENDplex™ magnetic capture beads (corresponding to Proinflammatory Chemokine or Inflammation Panel). Incubate at room temperature in the dark for 2 hours (specific time depends on the kit instructions), and vortex to ensure complete binding.
[0137] Separate the captured beads using a magnetic rack and discard the supernatant. Add an appropriate amount of washing buffer, gently resuspend the magnetic beads, and repeat the washing 2-3 times (according to kit instructions).
[0138] Add biotin-labeled detection antibody, incubate at room temperature in the dark for 1 hour, and vortex to mix. After washing to remove unbound antibody, add streptavidin-phycoerythrin (SA-PE), incubate at room temperature in the dark for 30 minutes, and vortex to mix.
[0139] Unbound SA-PE was washed away, and the magnetic beads were resuspended in buffer and transferred to flow cytometry tubes. PE fluorescence signals were detected on a Beckman Cytoflex flow cytometer, and the signal intensities of each cytokine were recorded.
[0140] Simultaneously detect serially diluted standards to generate a standard curve. Compare the sample signal intensity with the standard curve to quantitatively calculate the concentration of each cytokine (unit: pg / ml).
[0141] Use LEGENDplex™ data analysis software to automatically process streaming data.
[0142] 3. Experimental Results
[0143] Anti-Ly6G antibodies alleviate severe pneumonia caused by reinfection by depleting neutrophils and blocking NETs.
[0144] Twenty-four hours before reinfection, Anti-Ly6G antibody was injected via the tail vein to target exhausted neutrophils, and its intervention effect on the pathological damage of severe pneumonia in BA.5-XBB reinfected mice was evaluated. Results showed that compared to the Model (BA.5-XBB) after antibody treatment, the degree of inflammatory infiltration in the lungs of mice was significantly reduced. Figure 1 In the Anti-Ly6G antibody treatment group, the expression levels of cytokines IL-6, IFN-α, IFN-γ, TNF-α, and chemokines CCL2, CCL4, CXCL10, and GM-CSF were all significantly downregulated. Figure 2 MPO and citH3 are direct morphological markers of NETs, and their secretion is positively correlated with the degree of inflammatory damage in lung tissue. Using immunofluorescence staining to co-localize MPO+citH3+ double-positive cells in lung tissue, we found a significant decrease in neutrophil infiltration in the Anti-Ly6G antibody treatment group, and the number of MPO+citH3+ co-localized positive cells decreased by 87.89%, indicating that Anti-LY6G antibody treatment can effectively inhibit NET formation. Figure 3 ELISA results showed that Anti-Ly6G antibody treatment significantly reduced the expression levels of four key NETs-related proteins (citH3, NE, MPO-DNA complex, and PAD4) in lung tissue. Figure 4 The above results indicate that administration of Anti-Ly6G antibody can effectively inhibit the formation of NETs and alleviate lung tissue inflammation induced by BA.5-XBB reinfection.
[0145] The above description of the embodiments is only for understanding the method and core ideas of the present invention. It should be noted that those skilled in the art can make various improvements and modifications to the present invention without departing from the principles of the invention, and these improvements and modifications will also fall within the protection scope of the claims of the present invention.
Claims
1. Use of any one of: (1) a Ly6G antibody or a Ly6G antigen-binding fragment in the manufacture of a medicament for treating and / or preventing a SARS-CoV-2 infection; (2) a Ly6G antibody or a Ly6G antigen-binding fragment in the manufacture of a medicament for treating and / or preventing a disease or a condition caused by a SARS-CoV-2 infection.
2. Use according to claim 1, characterized in that, The antibody includes a monoclonal antibody, a polyclonal antibody, a recombinant antibody.
3. Use according to claim 1, characterized in that, The antigen-binding fragment includes a Fab, a Fab', a F(ab')2, a single-chain antibody scFv, a nanobody VHH.
4. Use according to claim 1, characterized in that, The SARS-CoV-2 infection includes a first SARS-CoV-2 infection and a multiple SARS-CoV-2 infection.
5. Use according to claim 4, characterized in that, The first SARS-CoV-2 infection and the multiple SARS-CoV-2 infection belong to different lineages of the same variant or different variants; Preferably, the first SARS-CoV-2 infection and the multiple SARS-CoV-2 infection belong to different lineages of the same variant; Preferably, the variant includes an Alpha variant, a Beta variant, a Gamma variant, a Delta variant, an Omicron variant, other variants; Preferably, the variant is selected from the Omicron variant; Preferably, the Omicron variant includes BA.1, BA.2, BA.3, BA.4, BA.5, or a descendant lineage thereof; Preferably, the BA.2 descendant lineage includes XBB; Preferably, the Omicron variant is selected from BA.5, XBB; Preferably, the first SARS-CoV-2 infection is selected from BA.5; Preferably, the multiple SARS-CoV-2 infection is selected from XBB.
6. Use according to any one of claims 1 to 5, characterized in that, The disease or condition caused by the SARS-CoV-2 infection is selected from one or more of: a respiratory infection, an acute respiratory syndrome, a pneumonia, a gastroenteritis, a cough, a fever, a chill, a vomiting, a headache, a chills, a shortness of breath, a cytokine storm; Preferably, the disease or condition caused by the SARS-CoV-2 infection is selected from a pneumonia; Preferably, the pneumonia is a severe SARS-CoV-2-induced pneumonia; Preferably, the severe SARS-CoV-2-induced pneumonia exhibits one or more of the following symptoms compared to a mild SARS-CoV-2-induced pneumonia: increased degree of pulmonary inflammatory infiltrates, increased cytokines, increased chemokines, increased NETs formation, increased expression level of NETs-associated proteins; Preferably, the NETs-associated proteins include citH3, NE, MPO-DNA, PAD4.
7. A pharmaceutical composition for treating and / or preventing a novel coronavirus infection or a disease or disorder caused by infection thereof, characterized by, The pharmaceutical composition is selected from the Ly6G antibody or the Ly6G antigen-binding fragment as described in any one of claims 1-3.
8. The pharmaceutical composition of claim 7, wherein, The pharmaceutical composition further includes a pharmaceutically acceptable carrier and / or an excipient.
9. Use of any one of: (1) a Ly6G antibody or a Ly6G antigen-binding fragment in the manufacture of a medicament for reducing the degree of pulmonary inflammatory infiltrates; (2) a Ly6G antibody or a Ly6G antigen-binding fragment in the manufacture of a medicament for reducing the expression level of cytokines or chemokines; Preferably, the cytokines include IL-6, IFN-a, IFN-g, TNF-a; Preferably, the chemokines comprise CCL2, CCL4, CXCL10, GM-CSF; (3) Use of a Ly6G antibody or Ly6G antigen-binding fragment in the preparation of a medicament for inhibiting NETs formation; (4) Use of a Ly6G antibody or Ly6G antigen-binding fragment in the preparation of a medicament for reducing the expression level of a NETs-related protein; Preferably, the NETs-related protein comprises citH3, NE, MPO-DNA, PAD4.
10. Any one of the following methods: (1) A method for reducing the expression level of a cytokine or chemokine in vitro, characterized by, The method comprises administering a Ly6G antibody or Ly6G antigen-binding fragment; (2) A method for inhibiting NETs formation in vitro, characterized in that the method comprises administering a Ly6G antibody or Ly6G antigen-binding fragment; (3) A method for reducing the expression level of a NETs-related protein in vitro, characterized in that the method comprises administering a Ly6G antibody or Ly6G antigen-binding fragment.
Citation Information
Patent Citations
Application of Ulixertinib in treating lung tissue inflammation caused by novel coronavirus
CN120789263A
Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and / or tslpr and / or ox40l and / or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
US20190125832A1
Prevention and treatment of infections including those caused by coronavirus
US20230084300A1
